Nicox S.A. reported net revenue results for the fourth quarter and full year of 2022. Net revenue for the fourth quarter of 2022 was €1.0 million (consisting entirely of net royalty payments). This compares to net revenue for the fourth quarter of 2021 of €3.5 million (€0.5 million of net royalty payments and a €3.0 million non-cash accounting adjustment initially recorded as deferred income following a licensing payment received from Ocumension Therapeutics in March 2020).

The net revenue for the full year 2022 was €3.3 million (consisting entirely of net royalty payments) compared to a net revenue for the full year 2021 of €7.2 million (€2.4 million in net royalties, €4.8 million in license payments).